Wednesday, September 30, 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

›
  In continuation of my update on  Ponatinib   Ponatinib is highly active when given to patients within 6 months of developing c...
Tuesday, September 29, 2015

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

›
MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Ph...
Monday, September 28, 2015

Scientists identify new agent to combat tuberculosis

›
(Griselimycin) Above pic: The protein forms a homodimeric ring (shown as blue cartoon & surface representation). Each...
Friday, September 25, 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

›
In continuation of my update on  dapagliflozin Results from a new study of Japanese patients with type 2 diabetes showed once-we...
Thursday, September 24, 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

›
In continuation of my update on Ibrutinib Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA®) improved p...
Wednesday, September 23, 2015

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

›
The Paediatric HIV Treatment Initiative welcomes this important step towards closing the treatment gap for children with HIV Infants a...
Tuesday, September 22, 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

›
In continuation of my update on  daclatasvir   The All Wales Medicines Strategy Group (AWMSG) has recommended Daklinza ® (daclatasvi...
Monday, September 21, 2015

PALOMA3 supports palbociclib use in advanced breast cancer

›
In continuation of my update on palbociclib ...  Advanced breast cancer patients who have failed prior endocrine treatment may rece...
Friday, September 18, 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

›
Amgen announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis ® (carfilzomib) for ...
Thursday, September 17, 2015

Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

›
Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphoc...
Wednesday, September 16, 2015

Possible New Combination Chemotherapy for Patients with Advanced Prostate Cancer

›
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate ...
Tuesday, September 15, 2015

Targeted drug can ‘diminish the suffering’ of myelofibrosis

›
Investigators further found that pacritinib could be used safely in patients with myelofibrosis who have thrombocytopenia, a life-threati...
Monday, September 14, 2015

Promising preliminary results for AKB-9778 in diabetic macular oedema

›
AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP), has a good safety and ef...
Friday, September 11, 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

›
In continuation of my update on  Ruxolitinib Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproli...
Thursday, September 10, 2015

Metformin can reduce risk of open-angle glaucoma in people with diabetes

›
In continuation of my update on  metformin Taking the medication metformin hydrochloride was associated with reduced risk of dev...